急性口服过量后活性炭胃肠去污的系统评价
该文是临床毒理学推荐协作组活性炭工作组对成人及儿童急性口服中毒后口服活性炭证据的系统评价,检索至2019年12月31日,纳入296项人体研究、118项动物研究和145项体外研究。83%的研究GRADE质量为低或极低,高质量证据集中于对乙酰氨基酚、苯巴比妥、卡马西平、强心苷(地高辛与夹竹桃)、乙醇、铁剂、水杨酸盐、茶碱、三环类抗抑郁药和丙戊酸盐。对照研究中48%在摄入1小时内给予首剂,而临床数据中97%首剂超过1小时;尽管存在异质性,许多临床场景中超过1小时给药仍报告有获益。未找到单次或多次活性炭最佳剂量的研究。
要点
- 高质量证据仅覆盖对乙酰氨基酚、苯巴比妥、卡马西平、强心苷(地高辛与夹竹桃)、乙醇、铁剂、水杨酸盐、茶碱、三环类抗抑郁药和丙戊酸盐等少数药物。
- 临床数据中首剂活性炭在摄入后超过1小时给药者占97%(n=1006),超过2小时者占36%(n=491),超过12小时者占4%(n=43)。
- 对照研究中首剂在摄入1小时内给药者占48%(n=2359),超过2小时者占36%(n=484)。
- 在临床场景中,许多情况下超过1小时给予活性炭仍报告有获益,但数据异质性大、总体证据质量偏低。
- 未发现评价单次或多次活性炭最佳给药剂量的研究,剂量方案缺乏证据支持。
适用人群与场景
- 纳入成人或儿童急性口服中毒患者,涉及已知药物中毒及未知或混合摄入人群;检索无语言限制,数据库检索自建库至2019年12月31日。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体的给药剂量、途径、频次或疗程;仅指出未找到单次或多次活性炭最佳给药方案的研究。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征。
研究设计与关键结果
- 系统评价:从22,950条题录中最终纳入296项人体研究、118项动物研究和145项体外研究,另含71项人体和2项动物不良事件研究。
- 时间数据:临床数据中首剂超过1小时占97%(n=1006)、超过2小时占36%(n=491)、超过12小时占4%(n=43);对照研究中1小时内占48%(n=2359)、超过2小时占36%(n=484)。
- 未找到单次或多次活性炭最佳剂量的研究;针对未知或混合摄入的研究因临床有意义中毒或死亡发生率低而受限,但许多临床场景报告超过1小时给药仍有获益。
证据类型、等级与局限
- 证据类型:系统评价,采用GRADE方法评估质量与偏倚风险;83%的研究为低或极低质量,仅少数药物有中等或高质量证据。
- 局限:数据异质性大;高质量证据仅集中于少数特定药物;未知或混合摄入研究受低毒性发生率限制;未找到最佳剂量研究;检索截止2019年12月31日。
对床旁实践的改变
- 对已知可吸附药物(如对乙酰氨基酚、卡马西平、苯巴比妥、茶碱、三环类抗抑郁药、丙戊酸盐等)中毒,不应仅因就诊超过1小时就放弃考虑活性炭,原文报告许多临床场景超过1小时仍有获益。
- 原文未提供剂量方案,不能据此改变单次或多次活性炭的具体给药剂量与频次;对未知或混合摄入者,因临床有意义中毒发生率低,证据受限,需个体化判断。
- 常见陷阱:把低或极低质量研究的获益结论外推为所有中毒的常规推荐,或把特定药物的高质量证据套用于未研究的新药。
指南或共识出处
- 原文提及美国临床毒理学会(AACT)、欧洲中毒中心与临床毒理学家协会(EAPCCT)及亚太医学毒理学会(APAMT)共同成立临床毒理学推荐协作组,并引用AACT/EAPCCT关于单次和多次活性炭的联合立场声明;原文未给出本系统评价的期刊发表年份。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The use of activated charcoal in poisoning remains both a pillar of modern toxicology and a source of debate. Following the publication of the joint position statements on the use of single-dose and multiple-dose activated charcoal by the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists, the routine use of activated charcoal declined. Over subsequent years, many new pharmaceuticals became available in modified or alternative-release formulations and additional data on gastric emptying time in poisoning was published, challenging previous assumptions about absorption kinetics. The American Academy of Clinical Toxicology, the European Association of Poison Centres and Clinical Toxicologists and the Asia Pacific Association of Medical Toxicology founded the Clinical Toxicology Recommendations Collaborative to create a framework for evidence-based recommendations for the management of poisoned patients. The activated charcoal workgroup of the Clinical Toxicology Recommendations Collaborative was tasked with reviewing systematically the evidence pertaining to the use of activated charcoal in poisoning in order to update the previous recommendations.
OBJECTIVES: The main objective was: Does oral activated charcoal given to adults or children prevent toxicity or improve clinical outcome and survival of poisoned patients compared to those who do not receive charcoal? Secondary objectives were to evaluate pharmacokinetic outcomes, the role of cathartics, and adverse events to charcoal administration. This systematic review summarizes the available evidence on the efficacy of activated charcoal.
METHODS: A medical librarian created a systematic search strategy for Medline (Ovid), subsequently translated for Embase (via Ovid), CINAHL (via EBSCO), BIOSIS Previews (via Ovid), Web of Science, Scopus, and the Cochrane Library/DARE. All databases were searched from inception to December 31, 2019. There were no language limitations. One author screened all citations identified in the search based on predefined inclusion/exclusion criteria. Excluded citations were confirmed by an additional author and remaining articles were obtained in full text and evaluated by at least two authors for inclusion. All authors cross-referenced full-text articles to identify articles missed in the searches. Data from included articles were extracted by the authors on a standardized spreadsheet and two authors used the GRADE methodology to independently assess the quality and risk of bias of each included study.
RESULTS: From 22,950 titles originally identified, the final data set consisted of 296 human studies, 118 animal studies, and 145 in vitro studies. Also included were 71 human and two animal studies that reported adverse events. The quality was judged to have a Low or Very Low GRADE in 469 (83%) of the studies. Ninety studies were judged to be of Moderate or High GRADE. The higher GRADE studies reported on the following drugs: paracetamol (acetaminophen), phenobarbital, carbamazepine, cardiac glycosides (digoxin and oleander), ethanol, iron, salicylates, theophylline, tricyclic antidepressants, and valproate. Data on newer pharmaceuticals not reviewed in the previous American Academy of Clinical Toxicology/European Association of Poison Centres and Clinical Toxicologists statements such as quetiapine, olanzapine, citalopram, and Factor Xa inhibitors were included. No studies on the optimal dosing for either single-dose or multiple-dose activated charcoal were found. In the reviewed clinical data, the time of administration of the first dose of charcoal was beyond one hour in 97% (n = 1006 individuals), beyond two hours in 36% (n = 491 individuals), and beyond 12 h in 4% (n = 43 individuals) whereas the timing of the first dose in controlled studies was within one hour of ingestion in 48% (n = 2359 individuals) and beyond two hours in 36% (n = 484) of individuals.
CONCLUSIONS: This systematic review found heterogenous data. The higher GRADE data was focused on a few select poisonings, while studies that addressed patients with unknown and or mixed ingestions were hampered by low rates of clinically meaningful toxicity or death. Despite these limitations, they reported a benefit of activated charcoal beyond one hour in many clinical scenarios.
参考来源
- Hoegberg LCG, Shepherd G, Wood DM, et al. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clin Toxicol (Phila). 2021. PMID: 34424785. doi:10.1080/15563650.2021.1961144
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。